Janux Therapeutics is exploring options including a potential sale, after receiving takeover interest from larger pharmaceutical companies, Dinesh Nair, Michelle Davis and Manuel Baigorri of Bloomberg report, citing people with knowledge of the matter. Janux is working with a financial adviser to evaluate possibilities including a sale, sources told Bloomberg. Janux is likely to draw interest from bigger drug companies seeking acquire new medicines to replenish their portfolios or expand into cancer treatments, the people said. Shares of Janux jumped 9% to $43.75 following the report before halting for volatility.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics initiated with a Buy at BTIG
- Cantor starts Janux at Overweight on ‘tremendous opportunity’
- Janux Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Janux Therapeutics price target raised to $48 from $24 at BofA
- Janux Therapeutics price target raised to $50 from $35 at H.C. Wainwright
